Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Endoxifen levels in Breast Cancer patients and testing for CYP2D6

SABCS 2008

10 - 14 Dec 2008

Published: 9 Jan 2009

Views: 18132

Rating:

Save

Dr John Hawse, Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine

Patients receiving tamoxifen therapy who can produce high levels of endoxifen have better survival than those producing low levels - why is this? Test needed for patients with CYP2D6 gene prior to administering tamoxifen

Related Videos

OncoAlert Round Up for August 11th - 17th, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for August 11th - 17th, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

Updates on HR-positive HER2-negative breast cancer

Dr Mariana Chavez - MD Anderson Cancer Center, Houston, USA

Updates on HR-positive HER2-negative breast cancer ( Dr Mariana Chavez - MD Anderson Cancer Center, Houston, USA )

Updates on triple-negative breast cancer and immunotherapy

Dr Avan Armaghani - Moffitt Cancer Center, Tampa, USA

Updates on triple-negative breast cancer and immunotherapy ( Dr Avan Armaghani - Moffitt Cancer Center, Tampa, USA )

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic...

Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City...

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer ( Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA )

ASCO 2023: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ASCO 2023: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

More from ecancer